Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1751
Beam Therapeutics
BEAM
$2.74B
| $9.04M | ﹤0.01% |
326,178
+12,551
| +4% | +$320K |
|
1752
Lincoln National
LNC
$8.67B
| $9.04M | ﹤0.01% |
202,942
-945,585
| -82% | -$39.4M |
|
1753
Enova International
ENVA
$6.52B
| $9.03M | ﹤0.01% |
57,466
-2,606
| -4% | -$339K |
|
1754
PUT
Philip Morris
PM
$294B
| $9.03M | ﹤0.01% |
56,300
| – | – |
|
1755
GFL Environmental
GFL
$15B
| $9.02M | ﹤0.01% |
209,906
-284,787
| -58% | -$12.7M |
|
1756
Moelis & Co
MC
$5.21B
| $9M | ﹤0.01% |
130,959
+9,832
| +8% | +$656K |
|
1757
Andersons Inc
ANDE
$2.21B
| $9M | ﹤0.01% |
169,182
+14,276
| +9% | +$698K |
|
1758
CALL
Dick's Sporting Goods
DKS
$18.1B
| $8.97M | ﹤0.01% |
45,300
-15,000
| -25% | -$3.27M |
|
1759
Chemed
CHE
$7.02B
| $8.96M | ﹤0.01% |
20,952
-1,922
| -8% | -$837K |
|
1760
Coursera
COUR
$1.53B
| $8.92M | ﹤0.01% |
1,212,036
+16,609
| +1% | +$145K |
|
1761
Veracyte
VCYT
$3.42B
| $8.91M | ﹤0.01% |
211,655
-30,697
| -13% | -$1.24M |
|
1762
Evercore
EVR
$12B
| $8.91M | ﹤0.01% |
26,187
-36,931
| -59% | -$11.9M |
|
1763
Axos Financial
AX
$5.72B
| $8.88M | ﹤0.01% |
103,107
+11,967
| +13% | +$986K |
|
1764
argenx
ARGX
$53.6B
| $8.85M | ﹤0.01% |
10,525
+10,257
| +3,827% | +$8.78M |
|
1765
Talos Energy
TALO
$2.58B
| $8.85M | ﹤0.01% |
803,139
+298,201
| +59% | +$3.12M |
|
1766
Macerich
MAC
$6.99B
| $8.84M | ﹤0.01% |
478,995
+7,729
| +2% | +$136K |
|
1767
Zeta Global
ZETA
$7.44B
| $8.83M | ﹤0.01% |
433,740
+106,038
| +32% | +$1.98M |
|
1768
PUT
Abercrombie & Fitch
ANF
$4.84B
| $8.81M | ﹤0.01% |
70,000
-735,700
| -91% | -$64.3M |
|
1769
Compass
COMP
$10.2B
| $8.79M | ﹤0.01% |
831,257
+96,489
| +13% | +$880K |
|
1770
PUT
CVS Health
CVS
$121B
| $8.79M | ﹤0.01% |
110,700
-608,400
| -85% | -$48M |
|
1771
ESCO Technologies
ESE
$7.79B
| $8.78M | ﹤0.01% |
44,955
+7,460
| +20% | +$1.57M |
|
1772
Dyne Therapeutics
DYN
$4.85B
| $8.78M | ﹤0.01% |
448,658
-32,043
| -7% | -$607K |
|
1773
Mirion Technologies
MIR
$3.88B
| $8.76M | ﹤0.01% |
374,006
-27,280
| -7% | -$680K |
|
1774
CALL
Marathon Petroleum
MPC
$100B
| $8.73M | ﹤0.01% |
53,700
-35,000
| -39% | -$6.54M |
|
1775
AutoNation
AN
$6.89B
| $8.73M | ﹤0.01% |
42,288
-52,407
| -55% | -$10.9M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.